BACKGROUND: Results from the Women's Health Initiative trial raise new questions regarding the effects of estrogen therapy (ET) and estrogen plus progestin therapy (EPT) on breast cancer risk. METHODS: We analyzed data from 126,638 females, ages 50 to 71 years at baseline, who completed two questionnaires (1995--1996 and 1996--1997) as part of the NIH-AARP Diet and Health Cohort Study and in whom 3,657 incident breast cancers were identified through June 30, 2002. Hormone-associated relative risks (RR) and 95% confidence intervals (CI) of breast cancer were estimated via multivariable regression models. RESULTS: Among thin women (body mass index < 25 kg/m2), ET use was associated with a significant 60% excess risk after 10 years of use. EPT was associated with a significantly increased risk among women with intact uteri, with the highest risk among current, long-term (> or = 10 years) users (RR, 2.44; 95% CI, 2.13-2.79). These risks were slightly higher when progestins were prescribed continuously than sequentially (< 15 days/mo; respective RRs of 2.76 versus 2.01). EPT associations were strongest in thin women, but elevated risks persisted among heavy women. EPT use was strongly related to estrogen receptor (ER)-positive tumors, requiring consideration of this variable when assessing relationships according to other clinical features. For instance, ER- ductal tumors were unaffected by EPT use, but all histologic subgroups of ER+ tumors were increased, especially low-grade and mixed ductal-lobular tumors. CONCLUSIONS: Both ET and EPT were associated with breast cancer risks with the magnitude of increase varying according to body mass and clinical characteristics of the tumors.
BACKGROUND: Results from the Women's Health Initiative trial raise new questions regarding the effects of estrogen therapy (ET) and estrogen plus progestin therapy (EPT) on breast cancer risk. METHODS: We analyzed data from 126,638 females, ages 50 to 71 years at baseline, who completed two questionnaires (1995--1996 and 1996--1997) as part of the NIH-AARP Diet and Health Cohort Study and in whom 3,657 incident breast cancers were identified through June 30, 2002. Hormone-associated relative risks (RR) and 95% confidence intervals (CI) of breast cancer were estimated via multivariable regression models. RESULTS: Among thin women (body mass index < 25 kg/m2), ET use was associated with a significant 60% excess risk after 10 years of use. EPT was associated with a significantly increased risk among women with intact uteri, with the highest risk among current, long-term (> or = 10 years) users (RR, 2.44; 95% CI, 2.13-2.79). These risks were slightly higher when progestins were prescribed continuously than sequentially (< 15 days/mo; respective RRs of 2.76 versus 2.01). EPT associations were strongest in thin women, but elevated risks persisted among heavy women. EPT use was strongly related to estrogen receptor (ER)-positive tumors, requiring consideration of this variable when assessing relationships according to other clinical features. For instance, ER- ductal tumors were unaffected by EPT use, but all histologic subgroups of ER+ tumors were increased, especially low-grade and mixed ductal-lobular tumors. CONCLUSIONS: Both ET and EPT were associated with breast cancer risks with the magnitude of increase varying according to body mass and clinical characteristics of the tumors.
Authors: A Schatzkin; A F Subar; F E Thompson; L C Harlan; J Tangrea; A R Hollenbeck; P E Hurwitz; L Coyle; N Schussler; D S Michaud; L S Freedman; C C Brown; D Midthune; V Kipnis Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: Polly A Newcomb; Linda Titus-Ernstoff; Kathleen M Egan; Amy Trentham-Dietz; John A Baron; Barry E Storer; Walter C Willett; Meir J Stampfer Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-07 Impact factor: 4.254
Authors: Sandra A Norman; Jesse A Berlin; Anita L Weber; Brian L Strom; Janet R Daling; Linda K Weiss; Polly A Marchbanks; Leslie Bernstein; Lynda F Voigt; Jill A McDonald; Giske Ursin; Jonathan M Liff; Ronald T Burkman; Kathleen E Malone; Michael S Simon; Suzanne G Folger; Dennis Deapen; Phyllis A Wingo; Robert Spirtas Journal: Cancer Causes Control Date: 2003-12 Impact factor: 2.506
Authors: Garnet L Anderson; Rowan T Chlebowski; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Margery Gass; Elizabeth Bluhm; Stephanie Connelly; F Allan Hubbell; Dorothy Lane; Lisa Martin; Judith Ockene; Thomas Rohan; Robert Schenken; Jean Wactawski-Wende Journal: Lancet Oncol Date: 2012-03-07 Impact factor: 41.316
Authors: Amanda I Phipps; Christopher I Li; Karla Kerlikowske; William E Barlow; Diana S M Buist Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: Maeve Mullooly; Zeina G Khodr; Cher M Dallal; Sarah J Nyante; Mark E Sherman; Roni Falk; Linda M Liao; Jeffrey Love; Louise A Brinton; Gretchen L Gierach Journal: Am J Epidemiol Date: 2017-12-15 Impact factor: 4.897
Authors: Anne Grundy; Abbey E Poirier; Farah Khandwala; Alison McFadden; Christine M Friedenreich; Darren R Brenner Journal: CMAJ Open Date: 2016-09-21
Authors: Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506